The review covered more than 17 million people vaccinated in the European Union and United Kingdom.
"A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with Covid-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country," the company said.
Meanwhile, the European Medicines Agency (EMA) considers the reports on side effects of the AstraZeneca vaccine. The issue is about information from a few EU countries on the blood clots of some vaccinated people.
The EMA has not confirmed yet the direct connection between the vaccines and blood clots. The experts on the basis of the preliminary data considered that the number of cases of blood-clotting after the vaccination with AstraZeneca is not higher than it is observed among the population – 22 cases per 3 million doses.
Due to this reason, seven EU counties stopped the use of the AstraZeneca vaccine; particularly, Denmark, Austria, Estonia, Lithuania, Luxembourg, Latvia and Cyprus. Norway is not an EU member but it also stopped the use of AstraZeneca. Bulgaria, Thailand and Romania also suspended vaccination with AstraZeneca.